$60.88
2.15% today
NYSE, Apr 04, 07:45 pm CET
ISIN
US4050241003
Symbol
HAE

Haemonetics Corporation Target price 2025 - Analyst rating & recommendation

Haemonetics Corporation Classifications & Recommendation:

Buy
82%
Hold
9%
Sell
9%

Haemonetics Corporation Price Target

Target Price $95.20
Price $62.22
Potential
Number of Estimates 10
10 Analysts have issued a price target Haemonetics Corporation 2026 . The average Haemonetics Corporation target price is $95.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 9 Analysts recommend Haemonetics Corporation to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Haemonetics Corporation stock has an average upside potential 2026 of . Most analysts recommend the Haemonetics Corporation stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Revenue Billion $ 1.31 1.36
12.01% 3.88%
EBITDA Margin 23.33% 30.94%
4.64% 32.64%
Net Margin 8.79% 12.19%
8.73% 38.70%

10 Analysts have issued a sales forecast Haemonetics Corporation 2025 . The average Haemonetics Corporation sales estimate is

$1.4b
Unlock
. This is
1.00% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.4b 0.23%
Unlock
, the lowest is
$1.3b 1.79%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.3b 12.01%
2025
$1.4b 3.88%
Unlock
2026
$1.3b 1.94%
Unlock
2027
$1.4b 8.44%
Unlock
2028
$1.6b 11.12%
Unlock

7 Analysts have issued an Haemonetics Corporation EBITDA forecast 2025. The average Haemonetics Corporation EBITDA estimate is

$421m
Unlock
. This is
27.67% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$452m 37.14%
Unlock
, the lowest is
$380m 15.23%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $305m 17.21%
2025
$421m 37.80%
Unlock
2026
$438m 4.15%
Unlock
2027
$472m 7.64%
Unlock
2028
$508m 7.60%
Unlock

EBITDA Margin

2024 23.33% 4.64%
2025
30.94% 32.64%
Unlock
2026
32.87% 6.24%
Unlock
2027
32.62% 0.76%
Unlock
2028
31.59% 3.16%
Unlock

6 Haemonetics Corporation Analysts have issued a net profit forecast 2025. The average Haemonetics Corporation net profit estimate is

$166m
Unlock
. This is
29.92% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$230m 79.92%
Unlock
, the lowest is
$147m 14.96%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $115m 2.23%
2025
$166m 44.10%
Unlock
2026
$197m 18.89%
Unlock
2027
$241m 22.12%
Unlock
2028
$267m 11.04%
Unlock

Net Margin

2024 8.79% 8.73%
2025
12.19% 38.70%
Unlock
2026
14.78% 21.25%
Unlock
2027
16.65% 12.65%
Unlock
2028
16.63% 0.12%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Earnings Per Share $ 2.29 3.30
2.23% 44.10%
P/E 18.85
EV/Sales 2.96

6 Analysts have issued a Haemonetics Corporation forecast for earnings per share. The average Haemonetics Corporation EPS is

$3.30
Unlock
. This is
29.92% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$4.57 79.92%
Unlock
, the lowest is
$2.92 14.96%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $2.29 2.23%
2025
$3.30 44.10%
Unlock
2026
$3.92 18.79%
Unlock
2027
$4.79 22.19%
Unlock
2028
$5.32 11.06%
Unlock

P/E ratio

Current 24.49 29.26%
2025
18.85 23.03%
Unlock
2026
15.86 15.86%
Unlock
2027
12.99 18.10%
Unlock
2028
11.70 9.93%
Unlock

Based on analysts' sales estimates for 2025, the Haemonetics Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.93 25.82%
2025
2.96 1.14%
Unlock
2026
3.02 1.98%
Unlock
2027
2.79 7.78%
Unlock
2028
2.51 10.01%
Unlock

P/S ratio

Current 2.28 33.31%
2025
2.30 1.01%
Unlock
2026
2.34 1.98%
Unlock
2027
2.16 7.78%
Unlock
2028
1.95 10.01%
Unlock

Current Haemonetics Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked Mar 18 2025
JMP Securities
Locked
Locked
Locked Feb 07 2025
Raymond James
Locked
Locked
Locked Feb 07 2025
Needham
Locked
Locked
Locked Feb 07 2025
Barrington Research
Locked
Locked
Locked Feb 07 2025
JP Morgan
Locked
Locked
Locked Dec 06 2024
Barrington Research
Locked
Locked
Locked Dec 04 2024
Analyst Rating Date
Locked
Needham:
Locked
Locked
Mar 18 2025
Locked
JMP Securities:
Locked
Locked
Feb 07 2025
Locked
Raymond James:
Locked
Locked
Feb 07 2025
Locked
Needham:
Locked
Locked
Feb 07 2025
Locked
Barrington Research:
Locked
Locked
Feb 07 2025
Locked
JP Morgan:
Locked
Locked
Dec 06 2024
Locked
Barrington Research:
Locked
Locked
Dec 04 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today